Upgrade to SI Premium - Free Trial

Biogen (BIIB) PT Raised to $227 at RBC Capital

May 27, 2026 5:42 AM
RBC Capital analyst Brian Abrahams raised the price target on Biogen (NASDAQ: BIIB) to $227.00 (from $222.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change